Lausanne, November 21, 2024 - Leman Biotech, a clinical-stage biotechnology company specializing in the development, production, and commercialization of innovative metabolic immunotherapies, has been selected to deliver both oral and poster presentations at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The ASH Annual Meeting is the world's largest and most comprehensive hematology conference, taking place this year from December 7–10, 2024, in San Diego, California.

Lausanne, November 14, 2024 - Leman Biotech, a clinical-stage biotechnology company focusing on the development, production, and commercialization of innovative metabolic immunotherapies, will deliver an oral presentation at the 7th Swiss Oncology & Hematology Congress (SOHC) 2024 annual meeting, to be held in Congress Center Basel, Switzerland, from November 20 - 22, 2024. We will present the clinical results from our first-in-human investigator-initiated clinical trials for Metabolically Armed CD19 CAR-T Cell therapy for relapsed or refractory B cell hematological malignancies. Our Director of Translational Research Dr. Karthik Sathiyanadan will deliver the presentation. 
 

Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), a clinical-stage biotechnology company committed to the research, development, production, and commercialization of innovative metabolic immunotherapies, has recently made significant progress in its investigator-initiated trial (IIT) of metabolically armored CD19 CAR-T cell therapy (Meta10-19 infusion). In this IIT study, several patients who had lost mobility or experienced paralysis due to advanced cancer achieved complete response (CR) and successfully regained their ability to walk.

For many years, immunotherapies such as CAR-T cell therapy and immune checkpoint inhibitors have primarily focused on activating type-1 immunity to eliminate cancer cells. In contrast, type-2 immunity, typically known for responding to parasitic infections, has traditionally been viewed as antagonistic to type-1 immunity and, consequently, as a promoter of tumor progression.

Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), a clinical-stage biotechnology company dedicated to the research, development, production, and commercialization of innovative metabolic immunotherapies, recently announced the successful treatment of the first pediatric patient enrolled in its investigator-initiated clinical trial (IIT). The patient, treated with an extremely low dose (1% of the conventional dose), achieved complete remission (CR) and was discharged without complications.

Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), a clinical-stage biotechnology company dedicated to the research, development, production, and commercialization of innovative metabolic immunotherapies, is pleased to announce the completion of new financing totaling USD 7 million in Angel+ and Angel++ rounds. New shareholders include Fuho Capital, Yunfan Technology Investment, and private financial investors, while original shareholders Tiantu Capital and XtalPi continue to support Leman Biotech. Additionally, Leman Biotech and its metabolically enhanced CAR-T projects have received various non dilutive grants amounting to approximately USD 2.7 million. To date, Leman Biotech has secured around USD 20 million in angel financing and project funding. This financing will primarily support the IND application of metabolically enhanced CAR-T cell therapy and the acceleration of clinical research of metabolically enhanced cell therapies for solid tumors.